Placebo-controlled Trial of Nimodipine in the Treatment of Acute Ischemic Cerebral Infarction.


Phase N/A Results

Trial Description

To assess the effects of oral nimodipine on the mortality rate and neurologic outcome of patients with an acute ischemic stroke.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Double-blind, placebo-controlled, multicenter trial involving 164 patients.

Patient Involvement

One hundred sixty-four patients were randomly allocated to receive either nimodipine tablets (30 mg qid.) or identical placebo tablets for 28 days. Treatment was always started <= 48 hours after the acute event.


Type Measure Time Frame Safety Issue
Primary The Mathew Scale (modified by Gelmers et al). Mortality rate and neurologic outcome after 28 days.